GBT Archives - Spark Newswire

2 minute read

Earnings

Global Blood Therapeutics’s Return On Capital Employed Overview

September 15, 10:10 AM

Benzinga Pro data, Global Blood Therapeutics (NASDAQ:GBT) reported Q2 sales of $71.55 million. Earnings fell to a loss of $82.47 million, resulting in a 1.29% decrease from last quarter.

GBT

2 minute read

Earnings

Global Blood Therapeutics’s Return On Capital Employed Overview

By Benzinga Insights

September 1, 10:13 AM

Global Blood Therapeutics (NASDAQ:GBT) brought in sales totaling $71.55 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 1.29%, resulting in a loss of $82.47 million.

GBT

1 minute read

Analysts See Softened Timelines For CRISPR Therapeutics’ Sickle Cell Candidate In US

By Vandana Singh

August 9, 3:26 PM

Barclays says that CRISPR Therapeutics AG’s (NASDAQ: CRSP) Q2 FY22 earnings release was largely incremental, highlighting the progress of multiple clinical programs, including the…

BLUE

1 minute read

RBC Capital Downgrades Global Blood Therapeutics to Sector Perform, Raises Price Target to $68.5

By Benzinga Newsdesk

August 9, 7:27 AM

RBC Capital analyst Gregory Renza downgrades Global Blood Therapeutics (NASDAQ:GBT) from Outperform to Sector Perform and raises the price target from $60 to $68.5.

GBT

1 minute read

Cantor Fitzgerald Downgrades Global Blood Therapeutics to Neutral, Lowers Price Target to $68.5

By Benzinga Newsdesk

August 9, 4:59 AM

Cantor Fitzgerald downgrades Global Blood Therapeutics (NASDAQ:GBT) from Overweight to Neutral and lowers the price target from $75 to $68.5.

GBT

1 minute read

Cowen & Co. Downgrades Global Blood Therapeutics to Market Perform, Raises Price Target to $68.5

By Benzinga Newsdesk

August 9, 4:56 AM

Cowen & Co. analyst Ritu Baral downgrades Global Blood Therapeutics (NASDAQ:GBT) from Outperform to Market Perform and raises the price target from $67 to $68.5.

GBT

1 minute read

Global Blood Therapeutics: Q2 Earnings Insights

By Benzinga Insights

August 8, 11:16 PM

Global Blood Therapeutics (NASDAQ:GBT) reported its Q2 earnings results on Monday, August 8, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

GBT

2 minute read

Why These Pfizer Analysts Like The Global Blood Therapeutics Deal

By Wayne Duggan

August 8, 2:50 PM

Pfizer Inc. (NYSE: PFE) shares were trading lower Monday after the drugmaker announced a $5.4-billion bid to acquire blood disorder drugmaker Global Blood Therapeutics Inc (NASDAQ: GBT).

BHVN